- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: hairy cell leukemia.
Displaying page 1 of 1.
EudraCT Number: 2005-005998-29 | Sponsor Protocol Number: ICGHCL 2004 | Start Date*: 2004-09-26 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SENESE | |||||||||||||
Full Title: FIVE- VERSUS SEVEN-DAY SUBCUTANEOUS ADMINISTRATION OF CLADRIBINE IN HAIRY CELL LEUKEMIA | |||||||||||||
Medical condition: Patients with histologically verified HCL classical HCL presence of HCs in the bone marrow and in the peripheral blood detected by positive TRAP staining and positive DBA44 and/or co-expression o... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005487-13 | Sponsor Protocol Number: HCL-PG01 | Start Date*: 2012-05-11 | |||||||||||
Sponsor Name:UNIVERSITA' DEGLI STUDI DI PERUGIA | |||||||||||||
Full Title: A phase II, multi-center, open label study of the clinical activity and safety of the BRAF-V600 inhibitor vemurafenib (PLX-4032) in previously treated patients with hairy cell leukemia (HCL) carry... | |||||||||||||
Medical condition: Hairy cell leukemia (HCL)carrying the BRAF-V600 mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003233-26 | Sponsor Protocol Number: CD-ON-CAT-8015-1053 | Start Date*: 2015-04-13 | ||||||||||||||||
Sponsor Name:MedImmune, LLC | ||||||||||||||||||
Full Title: A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia | ||||||||||||||||||
Medical condition: Hairy Cell Leukemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) ES (Completed) BE (Completed) IE (Completed) DE (Completed) CZ (Completed) PL (Completed) GR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001836-20 | Sponsor Protocol Number: HCL-PG04 | Start Date*: 2017-09-19 | |||||||||||
Sponsor Name:PROF.BRUNANGELO FALINI, DR.ENRICO TIACCI. DIPARTIMENTO DI MEDICINA, UNIVERSITA' DI PERUGIA | |||||||||||||
Full Title: STEP-WISE COMBINATION OF OBINUTUZUMAB, VEMURAFENIB AND COBIMETINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) PREVIOUSLY TREATED WITH PURINE ANALOGS OR UNFIT FOR CHEMOTHERAPY: A PHASE-2, SINGLE-ARM... | |||||||||||||
Medical condition: HCL patients carrying the BRAF-V600E mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001379-29 | Sponsor Protocol Number: HCL-PG02 | Start Date*: 2014-07-04 | |||||||||||
Sponsor Name:Dipartimento di Medicina | |||||||||||||
Full Title: A PHASE II OPEN LABEL SINGLE CENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF THE BRAF-V600 INHIBITOR DABRAFENIB (TAFINLAR) IN PREVIOUSLY TREATED PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) CARRYING... | |||||||||||||
Medical condition: Hairy cell leukemia (HCL)carrying the BRAF-V600E mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001864-12 | Sponsor Protocol Number: HCL-PG05 | Start Date*: 2023-01-09 | |||||||||||
Sponsor Name:DIPARTIMENTO DI MEDICINA, UNIVERSITà DI PERUGIA | |||||||||||||
Full Title: VEMURAFENIB + RITUXIMAB (VR) AS A CHEMOTHERAPY-FREE ALTERNATIVE TO CLADRIBINE + RITUXIMAB (CDAR) IN FRONT-LINE HAIRY CELL LEUKEMIA (HCL): A PHASE-2 RANDOMIZED MULTICENTER TRIAL | |||||||||||||
Medical condition: Previously untreated patients with diagnosis of HCL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001225-33 | Sponsor Protocol Number: UC-0105/1401 | Start Date*: 2014-07-21 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:UNICANCER | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Secured access to vemurafenib for patients with tumors harboring BRAF genomic alterations. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patient with BRAF V600 mutation determined on the primary and/or metastatic lesion in the following pathologies: . NSCLC . Ovarian cancer . Cholangiocarcinoma . Thyroid cancer . Prostatic canc... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003046-27 | Sponsor Protocol Number: HCL-PG03 | Start Date*: 2014-09-27 |
Sponsor Name:Dipartimento di Medicina | ||
Full Title: A PHASE II OPEN-LABEL SINGLE-CENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF THE BRAF-V600 INHIBITOR VEMURAFENIB (ZELBORAF) IN COMBINATION WITH THE B-CELL TARGETING ANTIBODY RITUXIMAB (MABTHERA... | ||
Medical condition: HAIRY CELL LEUKEMIA (HCL) CARRYING THE BRAF-V600E MUTATION | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004710-41 | Sponsor Protocol Number: AMLBFM0401 | Start Date*: 2006-11-26 | |||||||||||
Sponsor Name:St. Anna Kinderkrebsforschung | |||||||||||||
Full Title: Multizentrische Therapieoptimierungsstudie AML-BFM 2004 zur Behandlung der akuten myeloischen Leukämien bei Kindern und Jugendlichen Multicentric therapy optimizing study AML-BFM 2004 for the trea... | |||||||||||||
Medical condition: For acute myeloic leukaemia in children and juveniles improvment of treatment with new medications should be investigated: 1. Cladribine: originally licenced for hairy cell leukamia has shown good ... | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002692-16 | Sponsor Protocol Number: APL-B-012-02 | Start Date*: 2004-10-27 |
Sponsor Name:PharmaMar SA unipersonal | ||
Full Title: A Phase II Multicenter,Open-Label, Clinical And Pharmacokinetic Study Of Aplidin® As A 1-Hour Weekly IV Infusion, In Patients With Relapsed Or Refractory Indolent Non-Hodgkin’s Lymphoid Neoplasms. | ||
Medical condition: Non-Hodgkin’s Lymphomas (NHLs) relapsing or refractory | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-004657-11 | Sponsor Protocol Number: VI-Plt-01 | Start Date*: 2012-03-30 | |||||||||||
Sponsor Name:FONDAZIONE PROGETTO EMATOLOGIA | |||||||||||||
Full Title: Open label multicenter study of Eltrombopag for the treatment of Immune ThrombocytoPenia (ITP) secondary to Chronic Lymphoproliferative Disorders (LPDs) | |||||||||||||
Medical condition: Immune ThrombocytoPenia (ITP) secondary to Chronic Lymphoproliferative Disorders (LPDs) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001417-33 | Sponsor Protocol Number: 20040156 | Start Date*: 2004-10-19 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Randomized Open-Label Study of Darbepoetin alfa Administered Every Three Weeks with or without Parenteral Iron in Anemic Subjects with Nonmyeloid Malignancies Receiving Chemotherapy | |||||||||||||
Medical condition: Chemotherapy induced anemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SE (Completed) FI (Completed) AT (Completed) CZ (Completed) GB (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001705-87 | Sponsor Protocol Number: BRF117019 | Start Date*: 2014-03-06 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and ... | |||||||||||||
Medical condition: Mutations of BRAF V600E have been identified at a high frequency in melanoma, PTC, colorectal and ovarian cancers. Such mutations have also been reported in some rare cancers such as anaplastic t... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) SE (Completed) BE (Completed) AT (Completed) DK (Completed) NL (Completed) ES (Ongoing) NO (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
